New Class Action Lawsuit on Zocor alleging Severe Complications

According to court documents, on June 1st, 2012, Louisiana resident Irene Richardson filed a class action lawsuit in the U.S. District Court for the Eastern District of Louisiana (case no. 2:12-cv-01396) alleging that Zocor was sold without proper warnings about the risk of muscle injuries and rhabdomyolysis. Zocor, which is also known by the generic name “Simvastatin”, manufactured by Merck Pharmaceuticals, is used to reduce bad cholesterol (LDL) and increase good cholesterol (HDL). In June 2011, the FDA posed restrictions in the use of the highest approved dose of the cholesterol-lowering medication simvastatin (80 mg) because of increased risk of muscle damage. Now, AttorneyOne.com, a recognized authority on law, can provide helpful, proven advice and simple solutions including how to get in contact with legal counsel so anyone can easily and inexpensively deal with cases of Zocor severe adverse events. [http://www.attorneyone.com/zocor/

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Zocor: severe adverse events threat

Zocor: severe adverse events threat

Rhabdomyolysis is the most serious form of myopathy and can lead to severe kidney damage, kidney failure, and sometimes death.

San Diego, CA (PRWEB) June 20, 2012

The media spotlight is often a double-edged sword. No one knows this better than Irene Richardson. And yet, gossip and rumor-mongering aside, the real story here is being overlooked according to Sean Burke of AttorneyOne.

According to court documents, on June 1st, 2012, Louisiana resident Irene Richardson filed a class action lawsuit in the U.S. District Court for the Eastern District of Louisiana (case no. 2:12-cv-01396) alleging that Zocor was sold without proper warnings about the risk of muscle injuries and rhabdomyolysis. Zocor, which is also known by the generic name “Simvastatin”, manufactured by Merck Pharmaceuticals, is used to reduce bad cholesterol (LDL) and increase good cholesterol (HDL). Plaintiff claims she took Zocor or simvastatin for cholesterol from 2010 until approximately June 2011. According to the lawsuit, as a result from the defective and unreasonably dangerous condition of Zocor or simvastatin, the plaintiff fears she may suffer from muscle injury or rhabdomyolisis.

In June 2011, the FDA posed restrictions in the use of the highest approved dose of the cholesterol-lowering medication simvastatin (80 mg) because of increased risk of muscle damage. The FDA mentioned that patients taking simvastatin 80 mg daily have an increased risk of myopathy compared to patients taking lower doses of this drug or other drugs in the same class.

AttorneyOne.com, a recognized authority on law, can provide helpful advice and simple solutions including how to get in contact with legal counsel so that, in case of severe complications from Zocor, someone can easily and inexpensively deal with it. As Mr. Burke, director of Media Relations for AttorneyOne.com, added, “What all this information really illustrates is that potential threat from Zocor remains. For that reason, our focus should squarely fall on getting the word out and assisting people in finding the right legal assistance.”

In March 2010, the U.S. FDA issued a warning about the potential for increased risk of muscle injury, including rhabdomyolysis, from Zocor (simvastatin) 80 mg. Rhabdomyolysis is the most serious form of myopathy and can lead to severe kidney damage, kidney failure, and sometimes death.

AttorneyOne.com has further information on Zocor lawsuits including how to get in contact with legal counsel.

Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2012/6/prweb9616618.htm.